Clinical cfficacy of calcium channel blockers slow the third generation of lercanidipine in the treatment of patients with arterial hypertension

ML Maksimov, AI Malykhina - Kardiologiia, 2013 - europepmc.org
The review describes the classification, mechanisms of action, the effects of calcium channel
blockers slow and the clinical benefits of dihydropyridine calcium antagonists, the third
generation. Presented modern aspects of clinical pharmacology and research results on the
efficacy, safety and organoprotective lercanidipine.

Clinical efficacy of calcium channel blockers slow the third generation of lercanidipine in the treatment of patients with arterial hypertension and metabolic disorders …

GA Tabidze, TD Gezeli, TA Tsibadze… - Georgian Medical …, 2015 - europepmc.org
Arterial hypertension is the most common risk factor in patients with metabolic disorders. In
the selection of antihypertensive therapy it is necessary to consider not only the anti-
hypertensive and organoprotective effects of drugs and their metabolic effects, which has
prognostic value. Calcium antaginists, along. Lercanidipine related to the third generation
dihydripyridine calcium antagonist, has been much more selective for the so-called slow
calcium channels of vascular smooth muscle cells, which is associated with a good …
以上显示的是最相近的搜索结果。 查看全部搜索结果

Google学术搜索按钮

example.edu/paper.pdf
查找
获取 PDF 文件
引用
References